Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
B 48.28 1.49% 0.71
VCEL closed up 1.49 percent on Friday, February 26, 2021, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical VCEL trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Fell Below 20 DMA Bearish 1.49%
Earnings Movers Other 1.49%
Multiple of Ten Bearish Other 1.49%
Inside Day Range Contraction 1.49%
20 DMA Support Bullish -2.37%
Bullish Engulfing Bullish -2.37%
New Uptrend Bullish -2.37%
Earnings Movers Other -2.37%
Multiple of Ten Bearish Other -2.37%
Older End-of-Day Signals for VCEL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support about 17 hours ago
Down 2 % about 18 hours ago
Down 1% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
20 DMA Resistance about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vericel Corporation Description

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cells Heart Failure Cell Therapy Knee Burns Myopathy Cardiomyopathy Cartilage Osteochondritis Dissecans Severe Diseases

Is VCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 53.9803
52 Week Low 6.78
Average Volume 616,834
200-Day Moving Average 23.55
50-Day Moving Average 39.60
20-Day Moving Average 48.07
10-Day Moving Average 49.65
Average True Range 2.94
ADX 42.99
+DI 26.79
-DI 23.72
Chandelier Exit (Long, 3 ATRs ) 45.17
Chandelier Exit (Short, 3 ATRs ) 47.16
Upper Bollinger Band 53.27
Lower Bollinger Band 42.87
Percent B (%b) 0.52
BandWidth 21.64
MACD Line 2.60
MACD Signal Line 3.35
MACD Histogram -0.7513
Fundamentals Value
Market Cap 2.19 Billion
Num Shares 45.4 Million
EPS 0.00
Price-to-Earnings (P/E) Ratio 16093.33
Price-to-Sales 9.59
Price-to-Book 9.99
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.22
Resistance 3 (R3) 52.06 50.59 51.56
Resistance 2 (R2) 50.59 49.59 50.67 51.34
Resistance 1 (R1) 49.44 48.97 48.70 49.59 51.12
Pivot Point 47.97 47.97 47.60 48.05 47.97
Support 1 (S1) 46.81 46.97 46.08 46.97 45.44
Support 2 (S2) 45.34 46.35 45.42 45.22
Support 3 (S3) 44.19 45.34 45.00
Support 4 (S4) 44.34